Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This paper reviews the neurobiology of bipolar disorder (BD), particularly findings associated with impaired cellular resilience and plasticity. METHODS: PubMed/Medline articles and book chapters published over the last 20 years were identified using the following keyword combinations: BD, calcium, cytokines, endoplasmic reticulum (ER), genetics, glucocorticoids, glutamate, imaging, ketamine, lithium, mania, mitochondria, neuroplasticity, neuroprotection, neurotrophic, oxidative stress, plasticity, resilience, and valproate. RESULTS: BD is associated with impaired cellular resilience and synaptic dysfunction at multiple levels, associated with impaired cellular resilience and plasticity. These findings were partially prevented or even reversed with the use of mood stabilizers, but longitudinal studies associated with clinical outcome remain scarce. CONCLUSIONS: Evidence consistently suggests that BD involves impaired neural plasticity and cellular resilience at multiple levels. This includes the genetic and intra- and intercellular signalling levels, their impact on brain structure and function, as well as the final translation into behaviour/cognitive changes. Future studies are expected to adopt integrated translational approaches using a variety of methods (e.g., microarray approaches, neuroimaging, genetics, electrophysiology, and the new generation of -omics techniques). These studies will likely focus on more precise diagnoses and a personalized medicine paradigm in order to develop better treatments for those who need them most.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationMerikangas, K. R., Akiskal, H. S., Angst, J., Greenberg, P. E., Hirschfeld, R. M. A., Petukhova, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.543 · Cited by 2,399
Debette, S., & Markus, H. S. (2010) · BMJ · doi:10.1136/bmj.c3666 · Cited by 2,328
Psychiatric GWAS Consortium Bipolar Disorder Working Group, Sklar, P., Ripke, S., Scott, L. J., Andreassen, O. A., Cichon, S., Craddock, N., Edenberg, H. J., Nurnberger, J. I., Rietschel, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.943 · Cited by 1,344
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationBaum, A. E., Akula, N., Cabanero, M., Cardona, I., Corona, W., Klemens, B., Schulze, T. G., Cichon, S., Rietschel, M., Nöthen, M. M., et al. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002012 · Cited by 700
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564 · cited 1×
“…addition, two double-blind, placebo-controlled ketamine studies have been conducted in individuals with bipolar depression; both found that ketamine had rapid and sustained antidepressant effects, as well as antisuicidal effects, in bipolar depression (DiazGranados et al. 2010; Zarate et al. 2012).”
Self-citationOxidative stress markers in bipolar disorder: A meta-analysis
Andreazza, A. C., Kauer-Sant'Anna, M., Frey, B. N., Bond, D. J., Kapczinski, F., Young, L. T., & Yatham, L. N. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.04.013 · Cited by 526
Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia
Clay, H. B., Daws, S., & Konradi, C. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2010.08.007 · Cited by 399
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Self-citationSubgenual Cingulate Cortex Volume in First-Episode Psychosis
Hirayasu, Y., Shenton, M. E., Salisbury, D. F., Kwon, J. S., Wible, C. G., Fischer, I. A., Yurgelun-Todd, D., Zarate, C., Kikinis, R., Jolesz, F. A., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1091 · Cited by 301 · cited 1×
“In addition, reduced subgenual prefrontal cortex (PFC) volume was observed in BD, and also linked to treatment response (Drevets et al. 1997; Hirayasu et al. 1999; Sharma et al. 2003).”
Self-citationIs Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
Moore, G. J., Cortese, B. M., Glitz, D. A., Zajac-Benitez, C., Quiroz, J. A., Uhde, T. W., Drevets, W. C., & Manji, H. K. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03745 · Cited by 234
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Self-citationKato, T., Takahashi, S., Shioiri, T., Murashita, J., Hamakawa, H., & Inubushi, T. (1994) · Journal of Affective Disorders · doi:10.1016/0165-0327(94)90116-3 · Cited by 223
Ibrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 3×
“A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder .”
Self-citationEfficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study
Zarate, C. A., Singh, J. B., Carlson, P. J., Quiroz, J., Jolkovsky, L., Luckenbaugh, D. A., & Manji, H. K. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00530.x · Cited by 208 · cited 2×
“%) as early as 5 days; this effect continued to be signifi cant until study endpoint (Zarate et al. 2007).”
Self-citationBenedetti, F., Serretti, A., Pontiggia, A., Bernasconi, A., Lorenzi, C., Colombo, C., & Smeraldi, E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.11.022 · Cited by 184 · cited 1×
“Interestingly, in human studies, a GSK-3 gene polymorphism was associated with earlier onset of BD (Benedetti et al. 2005); see Li and Jope (2010) for a review of other studies investigating genetic variations in GSK-3 in BD.”
Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder
Kapczinski, F., Frey, B. N., Kauer-Sant’Anna, M., & Grassi-Oliveira, R. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.7.1101 · Cited by 181
Brennan, B. P., Hudson, J. I., Jensen, J. E., McCarthy, J., Roberts, J. L., Prescot, A. P., Cohen, B. M., Pope, H. G., Renshaw, P. F., & Öngür, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.191 · Cited by 168 · cited 1×
“Another small, open-label, add-on study of 14 subjects with bipolar depression found that riluzole signifi cantly improved depressive symptoms (Brennan et al. 2010).”
Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate
Cui, J., Shao, L., Young, L. T., & Wang, J.-F. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.010 · Cited by 160 · cited 1×
“Chronic lithium treatment was further shown to limit oxidative stress-induced cell death and to increase levels of the antioxidant protein glutathione in cultured cerebral cells (Shao et al. 2005; Cui et al. 2007).”
Angelucci, F., Aloe, L., Jiménez-Vasquez, P., & Mathé, A. A. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003468 · Cited by 157
Mizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145 · cited 2×
“It inhibits glutamate release and increases AMPA traffi cking by enhancing membrane insertion of GluR1 and GluR2, and increases glutamate reuptake and neurotrophic factor synthesis (Mizuta et al. 2001; Frizzo et al. 2004).”
Protein Kinase C Inhibitors: Rationale for Use and Potential in the Treatment of Bipolar Disorder
Zarate, C. A., & Manji, H. K. (2009) · CNS Drugs · doi:10.2165/00023210-200923070-00003 · Cited by 122
Self-citationLithium- and Valproate-Induced Alterations in Circadian Locomotor Behavior in Drosophila
Dokucu, M. E., Yu, L., & Taghert, P. H. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300764 · Cited by 96
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92 · cited 1×
“Similarly, both MRS (Ongur et al. 2008; Soeiro-de-Souza et al. 2012) and postmortem (Hashimoto et al. 2007; Machado-Vieira et al 2012) studies have found increased glutamate levels in diverse brain areas of individuals with BD. Therapeutic agents that affect glutamate levels have been shown to have…”
Self-citation
Cited by
Nasca, C., Bigio, B., Zelli, D., Nicoletti, F., & McEwen, B. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.96 · Cited by 194
Oxidative stress in early stage Bipolar Disorder and the association with response to lithium
de Sousa, R. T., Zarate, C. A., Zanetti, M. V., Costa, A. C., Talib, L. L., Gattaz, W. F., & Machado-Vieira, R. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.11.011 · Cited by 169
“It has been proposed a progressive course of Bipolar Disorder (BD) associated with longer illness duration, cognitive decline, decreased functioning and impaired cellular resilience leading to deleterious consequences on signal transduction and synaptic plasticity (Machado-Vieira et al., 2013).”
BackgroundSelf-citationRevisiting inflammation in bipolar disorder
Fries, G. R., Walss-Bass, C., Bauer, M. E., & Teixeira, A. L. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.006 · Cited by 147
Self-citationAnimal models of bipolar mania: The past, present and future
Logan, R. W., & McClung, C. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.041 · Cited by 136
Benedetti, F., Poletti, S., Locatelli, C., Mazza, E., Lorenzi, C., Vitali, A., Riberto, M., Brioschi, S., Vai, B., Bollettini, I., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.011 · Cited by 64
“Bipolar Disorder (BD) is associated with impaired synaptic function, cellular resilience and plasticity (Machado-Vieira et al., 2013).”
Metadata
- Authors
- Machado-Vieira, R., Soeiro-De-Souza, M. G., Richards, E. M., Teixeira, A. L., & Zarate, C. A.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2013-09-02
- Volume
- 15
- Issue
- 2
- Pages
- 84-95
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2129527456
- Cited by
- 69
- References
- 28
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.